A new class of increasingly popular weight-loss drugs has become a hot topic of discussion between employers and their brokers or advisers. The FDA‘s recent approval of Tirzepatide, the active ingredient found in the diabetes drug Mounjaro and newly approved weight-loss drug Zepbound, represents the latest example.
With the potential health benefits for employees, and as more drugs in this category become developed and approved, employers should strongly consider how — and if — these drugs will be covered in their benefits program.
